| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H18N4O5S2 |
| Molecular Weight | 458.511 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12SCC(C[N+]3=CC=C(C=C3)C(N)=O)=C(N1C(=O)[C@H]2NC(=O)CC4=CC=CS4)C([O-])=O
InChI
InChIKey=FMZXNVLFJHCSAF-DNVCBOLYSA-N
InChI=1S/C20H18N4O5S2/c21-17(26)11-3-5-23(6-4-11)9-12-10-31-19-15(18(27)24(19)16(12)20(28)29)22-14(25)8-13-2-1-7-30-13/h1-7,15,19H,8-10H2,(H3-,21,22,25,26,28,29)/t15-,19-/m1/s1
| Molecular Formula | C20H18N4O5S2 |
| Molecular Weight | 458.511 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Cefalonium is a 1st generation cephalosporin with a broad spectrum of actvity against Gram-positive and Gram-negative bacterias. The drug inhibits the bacterial cell wall synthesis by binding to penicillin binding proteins. Cefalonium is approved for routine dry cow therapy to treat existing sub-clinical infections and to prevent new infections which occur during the dry period.
Approval Year
PubMed
Patents
Sample Use Guides
1 syringe (250 mg) per quarter immediately after final milking.
Route of Administration:
Other
The activity of cefalonium against different bacterial strains was measured. The MIC90 values were: 0.125 ug/ml for Staphylococcus aureus, 0.0156 ug/ml for Streptococcus agalactiae, 0.0078 ug/ml for Streptococcus dysgalactiae, 0.06 ug/ml for Streptococcus uberis, 0.125 ug/ml for Arcanobacterium pyogenes, 2 ug/ml for Escherichia coli and Klebsiella spp.
